Authors:
Ochnio, JJ
Patrick, D
Ho, M
Talling, DN
Dobson, SR
Citation: Jj. Ochnio et al., Past infection with hepatitis A virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs, CAN MED A J, 165(3), 2001, pp. 293-297
Authors:
Nicoll-Griffith, DA
Silva, JM
Chauret, N
Day, S
Leblanc, Y
Roy, P
Yergey, JA
Dixit, R
Patrick, D
Citation: Da. Nicoll-griffith et al., Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: Studies with DFP, a cyclooxygenase-2 inhibitor, DRUG META D, 29(2), 2001, pp. 159-165
Authors:
Huber, HE
Robinson, RG
Watkins, A
Nahas, DD
Abrams, MT
Buser, CA
Lobell, RB
Patrick, D
Anthony, NJ
Dinsmore, CJ
Graham, SL
Hartman, GD
Lumma, WC
Williams, TM
Heimbrook, DC
Citation: He. Huber et al., Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors, J BIOL CHEM, 276(27), 2001, pp. 24457-24465
Authors:
Prasit, P
Wang, Z
Brideau, C
Chan, CC
Charleson, S
Cromlish, W
Ethier, D
Evans, JF
Ford-Hutchinson, AW
Gauthier, JY
Gordon, R
Guay, J
Gresser, M
Kargman, S
Kennedy, B
Leblanc, Y
Leger, S
Mancini, J
O'Neill, GP
Ouellet, M
Percival, MD
Perrier, H
Riendeau, D
Rodger, I
Tagari, P
Therien, M
Vickers, P
Wong, E
Xu, LJ
Young, RN
Zamboni, R
Boyce, S
Rupniak, N
Forrest, N
Visco, D
Patrick, D
Citation: P. Prasit et al., The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, BIOORG MED, 9(13), 1999, pp. 1773-1778
Authors:
Spence, S
Anderson, C
Cukierski, M
Patrick, D
Citation: S. Spence et al., Teratogenic effects of the endothelin receptor antagonist L-753,037 in therat. (vol 13, pg 15, 1999), REPROD TOX, 13(3), 1999, pp. 237-237
Authors:
Kohal, RJ
De LaRosa, M
Patrick, D
Hurzeler, MB
Caffesse, RG
Citation: Rj. Kohal et al., Clinical and histologic evaluation of submerged and nonsubmerged hydroxyapatite-coated implants: A preliminary study in dogs, INT J O M I, 14(6), 1999, pp. 824-834
Authors:
Chan, CC
Boyce, S
Brideau, C
Charleson, S
Cromlish, W
Ethier, D
Evans, J
Ford-Hutchinson, AW
Forrest, MJ
Gauthier, JY
Gordon, R
Gresser, M
Guay, J
Kargman, S
Kennedy, B
Leblanc, Y
Leger, S
Mancini, J
O'Neill, GP
Ouellet, M
Patrick, D
Percival, MD
Perrier, H
Prasit, P
Rodger, I
Tagari, P
Therien, M
Vickers, P
Visco, D
Wang, Z
Webb, J
Wong, E
Xu, LJ
Young, RN
Zamboni, R
Riendeau, D
Citation: Cc. Chan et al., Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J PHARM EXP, 290(2), 1999, pp. 551-560